Last reviewed · How we verify

Omaveloxolone Ophthalmic Suspension 1%

Biogen · Phase 2 active Small molecule

Omaveloxolone Ophthalmic Suspension 1% is a Small molecule drug developed by Biogen. It is currently in Phase 2 development. Also known as: RTA 408 Ophthalmic Suspension 1%.

Omaveloxolone Ophthalmic Suspension 1% is a novel therapy developed by Biogen to prevent corneal endothelial cell loss following cataract surgery. Currently in Phase 2 trials, it shows promise in reducing post-surgical complications and improving patient outcomes. The drug has not yet received FDA approval but has completed a pivotal trial with positive results.

At a glance

Generic nameOmaveloxolone Ophthalmic Suspension 1%
Also known asRTA 408 Ophthalmic Suspension 1%
SponsorBiogen
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Omaveloxolone Ophthalmic Suspension 1%

What is Omaveloxolone Ophthalmic Suspension 1%?

Omaveloxolone Ophthalmic Suspension 1% is a Small molecule drug developed by Biogen.

Who makes Omaveloxolone Ophthalmic Suspension 1%?

Omaveloxolone Ophthalmic Suspension 1% is developed by Biogen (see full Biogen pipeline at /company/biogen).

Is Omaveloxolone Ophthalmic Suspension 1% also known as anything else?

Omaveloxolone Ophthalmic Suspension 1% is also known as RTA 408 Ophthalmic Suspension 1%.

What development phase is Omaveloxolone Ophthalmic Suspension 1% in?

Omaveloxolone Ophthalmic Suspension 1% is in Phase 2.

Related